

Pathway to Success Guide

See the structure behind our
evidence-aligned care pathway.

Vivio's Five Pillar Pathway to Success

Identify

Identify patients at risk for HF without a known diagnosis

- Adults with HF risk factors and no established HF diagnosis or recent testing
- Common signals: hypertension, diabetes, obesity, CKD, OSA, prior cardiotoxic exposure

Assess

Assess risk and symptom burden with pragmatic diagnostics

- Perform Ventric Vivio assessment
- Administer KCCQ to quantify symptom burden and functional impact
- Establish baseline physiologic and patient-reported status and consider PMH

Diagnose

Apply appropriate HF diagnosis based on findings

- Apply appropriate HF diagnosis based on findings:
 - I50.1 when Vivio findings align with HF and **KCCQ indicates evidence** of symptoms
 - I50.1 when Vivio findings suggest elevated filling pressure, but KCCQ is **negative** for symptoms
- Document diagnostic rationale to support longitudinal management

Manage

Initiate evidence-aligned management and care escalation as needed

- Initiate or escalate GDMT as indicated
- If indicated, refer to cardiology for diagnostic complexity, or escalation
- Evaluate and address underlying contributors
 - Hypertension
 - Obesity
 - Sleep apnea
 - CKD
 - Physical inactivity
 - Substance use history

Optimize

Reassess and refine management over time

- Annual re-evaluation for patients with HF risk or prior abnormal findings
- Reassess for ANY new or worsening symptoms
- Use Vivio to guide GDMT optimization, diuretic needs, or care escalation
- Support proactive management and avoidance of decompensation

LVEDP Elevation is the Hallmark of HF

HF is a *hemodynamic disease* that leads to structural changes and dysfunction

Risk Factors for HF Development:

- Age
- Known Cardiovascular Disease
 - Coronary artery disease
 - Stroke
 - Afib/AFL
 - Peripheral Arterial Disease
- Hypertension
- Diabetes
- Obesity or Metabolic Syndrome
- CKD/ESRD
- Cardiotoxic Medication Use
- Prior Thoracic Radiation Therapy
- Tobacco Use
- Family History
- Obstructive Sleep Apnea
- Other (e.g. HIV, COVID, Amyloid, etc.)

- Myocyte hypertrophy
- Interstitial fibrosis
- Endothelial dysfunction
- Cardiomyocyte loss

Vivio®

Worsening Heart Failure

Acquired Mitral Regurgitation

Progressive LV Remodeling

LV Strain (detectable by imaging)

Left Atrial Enlargement (detectable by imaging)

Left Ventricular Hypertrophy (detectable by imaging)

Valvular Heart Disease (detectable by imaging)

Natriuretic Peptide Lab Assays (widely variable based on cutoff and co-morbidities)

LVEDP Elevation: Gold Standard Physiologic definition of HF
regardless of cause HFpEF, HFrEF, and/or Valvular Heart Disease

KCCQ-12 Scores: 100 90 80 70 60 50 40 30 20 10 0

NYHA Classification: Class I Class I/II Class II Class II/III Class III Class III/IV Class IV

1-yr risk of Death or Hospitalization: 16% 25% 34% 42% 46% 48% 50% 51% 52% 53%

ACC/AHA Heart Failure Stage

Stage A HF
(At-risk for HF)

Stage B HF
(Asymptomatic Structural Heart Disease)

Stage C HF
(Symptomatic HF)

Stage D HF
(Advanced HF)

Early HF Detection and the Limitations of Echo

Early HF is a *hemodynamic disease* that Echo may lack sensitivity to detect

Resting Echo Misses a Large Fraction of True HFpEF

- Echo detects only 34–60% of invasively confirmed HFpEF
- 40–66% false negatives vs catheterization~33% labeled “normal” by ASE criteria despite confirmed HFpEF
- Among “normal/Grade 1”:
>60% have elevated PCWP ≥ 15 mmHg

Implication

Structural/diastolic grading lags underlying hemodynamics

Stress Echo Improves Sensitivity, but Falls Short

- Sensitivity \uparrow to ~90% but:
 - Specificity drops to ~71%
 - Overall discrimination weak (C-stat ~0.65)
- In mild disease (Grade 1 DD):
~90% false-negative rate with stress criteria

Implication

Even “optimized” echo fails in early disease where decisions matter

Echo Parameters may not Reflect LVEDP

- E/e' correlation with LVEDP:
 $r \approx 0.56$ (modest)
- Diagnostic accuracy: AUC 0.5–0.7 (low) for most parameters
- Best-case (LAVI, E/e'): 0.7–0.9 (moderate)

Implication

Echo precision lacks reliable measurement for early detection

Hemodynamics Reveal Disease Earlier Than Imaging


- ~1/3 of HFpEF patients have normal resting pressures with abnormalities only with exertion
- Early HFpEF often presents as:
 - “Unexplained dyspnea”
 - Normal echo + elevated LVEDP

Implication

Echo appears “normal” precisely when intervention opportunity is highest

Assess & Diagnose

Assess risk and symptom burden with pragmatic diagnostics



Manage and Optimize | “PCP Management Guide”

Initiate evidence-aligned management and care escalation as needed

Mild Findings | Stage B HF Management

Abnormal
Vivio ≥ 18

+

KCCQ = 100

1

Prevent progression to symptomatic HF

Initiate cardioprotective therapy as indicated

A. SGLT2 inhibitor if T2DM or CKD present

Consider adding/optimizing:

B. ARB or ACEi, particularly in T2DM and/or CKD

C. nsMRA especially in T2DM and CKD

Reinforce lifestyle modification and risk factor reduction

2

Consider referral to Pharmacy or Focused Disease Management Programs for support

- Hypertension control
- CKD management
- Obesity management and weight reduction strategy
- Educate on daily weights and sodium awareness
- Physical activity counseling and structured exercise

3

Follow-Up Optimization Strategy

- Reassess with Vivio **annually or sooner** if symptoms emerge
- Maintain **proactive surveillance, GDMT optimization** and **lifestyle changes**.

Additional Considerations:

- **Optional echocardiography**^{\$\$} in next 12 months, or if clinical suspicion of other cardiac pathology
- **Optional** Sleep apnea assessment

^{\$} **Limitation of Echo:** Early HF is a hemodynamic disease that Echo may lack sensitivity to detect

^{*} **Diagnostic Value of Echocardiograms and advanced testing:** To characterize other contributing factors including valvular disease, distinguish potential pEF vs rEF trajectory, evaluate for infiltrative cardiomyopathy (e.g., amyloid), right heart dysfunction, obstructive cardiomyopathy, wall motion abnormality or great vessel disease

Manage and Optimize | “PCP Management Guide”

Initiate evidence-aligned management and care escalation as needed

Mild to Moderate Findings | Stage C HF Management

Abnormal
Vivio ≥ 18

+

KCCQ 80-99

1

Initiate GDMT by starting three pillars without delay:

A. SGLT2 inhibitor

B. ARB or ACEi

C. nsMRA especially in T2DM and CKD

Reinforce **lifestyle modification** and risk factor reduction

2

Refer to *Pharmacy or Focused Disease Management Programs for support:*

- Hypertension control
- CKD management
- Obesity management and weight reduction strategy
- Educate on daily weights and sodium awareness
- Physical activity counseling and structured exercise

3

Follow-Up Optimization Strategy

- Reassess with Vivio **annually or sooner** if symptoms change
- Maintain **proactive surveillance, GDMT optimization** and **lifestyle changes.**
- Achieve GDMT maximally tolerated target dosage within 3–6 months

Additional Considerations:

- **Consider** echocardiography^{§*} in next 12 months, or sooner if clinical symptoms change or based on clinical suspicion of other cardiac pathology
- **Consider** Sleep apnea assessment
- **Consider** Cardiology referral if:
 - Symptom progression despite therapy
 - Suspected or confirmed new cardiac pathology
 - Desired to initiate beta blocker therapy (LVEF determination required)
 - Potential conversion current ARB/ACEi therapy to ARNI+ARB regimen

[§] **Limitation of Echo:** Early HF is a hemodynamic disease that Echo may lack sensitivity to detect

* **Diagnostic Value of Echocardiograms and advanced testing:** To characterize other contributing factors including valvular disease, distinguish potential pEF vs rEF trajectory, evaluate for infiltrative cardiomyopathy (e.g., amyloid), right heart dysfunction, obstructive cardiomyopathy, wall motion abnormality or great vessel disease

Manage and Optimize | “PCP Management Guide”

Initiate evidence-aligned management and care escalation as needed

Moderate to Significant Findings | Stage C HF Management

Abnormal
Vivio ≥ 18

+

KCCQ 60-79

1

Initiate/Optimize GDMT among three pillars without delay:

- A. SGLT2 inhibitor
- B. ARNI preferred or ACEi or ARB, if ARNI not feasible
- C. nsMRA especially in T2DM and CKD

Reinforce lifestyle modification and risk factor reduction

2

Stabilize Volume and Symptom Burden

- Consider Loop Diuretic for congestion
- Educate on daily weights and sodium awareness

3

Refer to Cardiology, Pharmacy or Focused Disease Management Programs for support:

- Hypertension control
- CKD management
- Obesity management and weight reduction strategy
- Physical activity counseling and structured exercise
- Consider echocardiography^{§*} in next 3-6 months, or sooner if clinical symptoms change or based on clinical suspicion of other cardiac pathology
- Consider beta-blocker based on LVEF determination

4

Follow-Up Optimization Strategy

- Reassess with Vivio annually or sooner if symptoms change
- Maintain proactive surveillance, GDMT optimization and lifestyle changes.
- Achieve GDMT maximally tolerated target dosage within 3-6 months

Additional Considerations:

- Consider Sleep apnea assessment
- Consider Cardiology escalation if:
 - Symptom progression despite therapy
 - Suspected or confirmed new cardiac pathology
- Consider referral and qualification for cardiac rehabilitation

§ **Limitation of Echo:** Early HF is a hemodynamic disease that Echo may lack sensitivity to detect

* **Diagnostic Value of Echocardiograms and advanced testing:** To characterize other contributing factors including valvular disease, distinguish potential pEF vs rEF trajectory, evaluate for infiltrative cardiomyopathy (e.g., amyloid), right heart dysfunction, obstructive cardiomyopathy, wall motion abnormality or great vessel disease

Manage and Optimize | “PCP Management Guide”

Initiate evidence-aligned management and care escalation as needed

Significant Findings | Stage C or D HF Management

Abnormal
Vivio ≥ 18

+

KCCQ < 60

1

Consider Cardiology referral for evaluation and management

2

Stabilize Volume and Symptom Burden

- **Consider** Loop Diuretic for congestion
- Educate on daily weights and sodium awareness

Initiate/Optimize GDMT among three pillars without delay:

- A. SGLT2 inhibitor
- B. ARNI preferred or ACEi or ARB, if ARNI not feasible
- C. MRA (nsMRA or sMRA)

Reinforce lifestyle modification and risk factor reduction

3

Refer to Cardiology, Pharmacy or Focused Disease Management Programs for support:

- **Recommend** echocardiography^{§*} as soon as possible
- **Initiate** beta-blocker therapy based on LVEF determination
- Ensure alignment with cardiology
- Control risk factors and comorbid conditions

4

Follow-Up Optimization Strategy

- **Maintain** alignment with cardiology
- **Reassess** with Vivio **annually or sooner** if symptoms change
- **Maintain** proactive surveillance, GDMT optimization and lifestyle changes.
- **Achieve** GDMT maximally tolerated target dosage within 3–6 months
- Adjust diuretics based on volume status and response

Additional Considerations:

- **Consider** Sleep apnea assessment
- **Consider** Cardiology escalation if:
 - Symptom progression despite therapy
 - Suspected or confirmed new cardiac pathology
- **Consider** referral and qualification for cardiac rehabilitation

§ **Limitation of Echo:** Early HF is a hemodynamic disease that Echo may lack sensitivity to detect

* **Diagnostic Value of Echocardiograms and advanced testing:** To characterize other contributing factors including valvular disease, distinguish potential pEF vs rEF trajectory, evaluate for infiltrative cardiomyopathy (e.g., amyloid), right heart dysfunction, obstructive cardiomyopathy, wall motion abnormality or great vessel disease

GDMT Reference Table

Evidence-Based Therapies in Patients with Elevated LVEDP with Common Comorbidities

| Drug Class | CKD | T2DM | Obesity | HTN | ASCVD | Worsening HF Risk |
|---|--------------------------------|-------------------|---------|---------------------|-------------------|---------------------|
| SGLT2i | ✓ ✓ | ✓ ✓ | ✓ | ✓ | ✓ | ✓ ✓ |
| nsMRA | ✓ (monitor K ⁺) | ✓ | | | | ✓ ✓ |
| sMRA (alternative if nsMRA not tolerated) | ✓ (monitor K ⁺) | | | ✓ | | ✓ ✓ |
| ARNi | ✓ (HFrEF only) | ✓ (HFrEF only) | | ✓ ✓ (HFrEF only) | ✓ (HFrEF only) | ✓ ✓ (HFrEF only) |
| ARB | ✓ | ✓ | | ✓ ✓ | ✓ | ✓ |
| ACEi | ✓ | ✓ | | ✓ ✓ | ✓ ✓ | ✓ |
| Adjunct Therapies if Indicated: | | | | | | |
| GLP-1 RA | ✓ | ✓ ✓ | ✓ ✓ | ✓ | ✓ ✓ | |
| Loop diuretic | ✓ | | | | | ✓ ✓ |
| Beta-Blockers | | | | ✓ | ✓ | ✓ (HFrEF only) |

| Drug Class | Drug Name | Initial Dose | Target Dose | Titration Comments |
|---|--|----------------------|-----------------------|--|
| SGLT2 Inhibitors | Dapagliflozin (Farxiga®) | 10 mg daily | 10 mg daily | Titration not required |
| | Empagliflozin (Jardiance®) | 10 mg daily | 10 mg daily | |
| nsMRA | Finerenone (Kerendia®) | 10-20mg daily* | 40 mg daily | Titration to goal every 4 weeks dependent on potassium levels and renal function |
| sMRA | Spironolactone | 12.5-25 mg daily* | 25-50 mg daily | |
| | | Eplerenone | 25 mg daily | 50 mg daily |
| ARNI | Sacubitril/Valsartan (Entresto®) | 24/26 mg twice daily | 97/103 mg twice daily | Titrate every 2-4 weeks |
| ARBs | Candesartan | 4-8 mg daily | 32 mg daily | Titrate as tolerated to goal BP |
| | Valsartan | 40 mg twice daily | 160 mg twice daily | |
| | Irbesartan | 75-150 mg daily | 300 mg daily | |
| ACE Inhibitors | Enalapril | 2.5 mg twice daily | 10-20 mg twice daily | Titrate as tolerated to goal BP |
| | Lisinopril | 2.5-5 mg daily | 40 mg daily | |
| | Ramipril | 1.25-2.5 mg daily | 10 mg daily | |
| Adjunct Therapies if Indicated: | | | | |
| GLP-1 RAs (Obesity-related HFpEF only with BMI ≥30) | Tirzepatide (Zepbound®) | 2.5 mg weekly | 15 mg weekly | Titrate every 4 weeks |
| | Semaglutide (Wegovy®) | 0.25 mg weekly | 2.4 mg weekly | |
| Loop Diuretics | Furosemide, Bumetanide, Torsemide, and Furoscix® (subQ) | varies | varies | Titrate to euvolemia |
| Beta-Blockers | Not recommended unless concurrent AF, CAD, or post-MI | ---- | ---- | NA |

* Consider renal dose adjustments and close monitoring especially in patients with GFR <60 mL/min

GDMT Reference Table | HFrEF

| Drug Class | Drug Name | Initial Dose | Target Dose | Titration Comments | Hospitalization Relative Risk Reduction | Mortality Relative Risk Reduction | Other Notable Outcomes |
|---|---|------------------------------|----------------------------|---|---|--|---|
| SGLT2 Inhibitors (COR I) | Dapagliflozin (Farxiga®) | 10 mg daily | 10 mg daily | Titration not required | 28-31% | 13% | <ul style="list-style-type: none"> Renal protection: 38% decrease in composite endpoint KCCQ improvement: +2-3 pts |
| | Empagliflozin (Jardiance®) | 10 mg daily | 10 mg daily | | | | |
| ACE Inhibitors (COR I) | Enalapril | 2.5 mg twice daily | 10-20 mg twice daily | Titrate as often as weekly | 30% | 16% | <ul style="list-style-type: none"> Prevents LV remodeling Modest LVEF improvement Decrease in progressive HF death |
| | Lisinopril | 2.5-5 mg daily | 40 mg daily | | | | |
| | Ramipril | 1.25-2.5 mg daily | 10 mg daily | | | | |
| ARBs (COR I) | Candesartan | 4-8 mg daily | 32 mg daily | Titrate as often as weekly | 24% | NS | <ul style="list-style-type: none"> Alternative to ACEi AND ARNi not feasible Similar remodeling prevention to ACEi |
| | Valsartan | 40 mg twice daily | 160 mg twice daily | | | | |
| | Losartan | 25-50 mg daily | 150 mg daily | | | | |
| ARNI (COR I) | Sacubitril/valsartan | 24/26 mg twice daily | 97/103 mg twice daily | Titrate every week | 21%* | 20% (CV Death) 16% (All-cause) | <ul style="list-style-type: none"> Decrease in sudden cardiac death by 20% Decrease in Ventricular arrhythmias by 24% Superior in reverse LV remodeling vs ACEi KCCQ improvement +3-5 pts |
| MRAs (COR I) | Spiroonolactone* | 12.5-25 mg daily* | 25-50 mg daily | Titration to goal every 4 weeks dependent on potassium levels and renal function | 37% | 27% | <ul style="list-style-type: none"> Decrease in sudden cardiac death by 23% Antifibrotic effects Caution: hyperkalemia risk 2X increase |
| | Eplerenone | 25 mg daily | 50 mg daily | | | | |
| | Finerenone (Kerendia®)* | 10-20mg daily* | 40 mg daily | Ongoing trials (FINALITY-HF) in HFrEF patients who cannot tolerate steroidal MRAs | | | |
| Beta-Blockers (COR I) | Carvedilol | 3.125 mg twice daily | 25-50 mg twice daily | Titrate as often as every 2 weeks | 35% | 34% | <ul style="list-style-type: none"> Decrease in sudden cardiac death by 31% Superior in reverse LV remodeling Decrease in Ventricular arrhythmias |
| | Metoprolol succinate | 12.5-25 mg daily | 200 mg daily | | | | |
| | Bisoprolol | 1.25 mg daily | 10 mg daily | | | | |
| QUADRUPLE THERAPY (SGLT2i + ARNI + BB + MRA) | | | | | 68% | 50% (CV Death) 47% (All-cause) | |
| Loop Diuretics (COR I) | Furosemide, Bumetanide, Torsemide, Furoscix® (subQ) | varies | varies | Titrate to euvolemia | ---- | ---- | ---- |
| Other Notables | Hydralazine/Isosorbide Dinitrate (COR I) | 20/37.5 mg three times daily | 40/75 mg three times daily | Titrate as tolerated | 33% | 43% | <ul style="list-style-type: none"> Self-identified Black patients with NYHA III-IV OR for ACEi/ARB/ARNi intolerance |
| | Ivabradine (Corlanor®) (COR IIa) | 2.5-5 mg twice daily | 7.5 mg twice daily | Titrate to HR 50-60 bpm | 26% | NS | <ul style="list-style-type: none"> Requires sinus rhythm + HR ≥70 bpm on max blocker |
| | Vericiguat (COR IIb) | 2.5 mg daily | 10 mg daily | Titrate every 2 weeks | 10% | NS | <ul style="list-style-type: none"> GDMT adjunct in high-risk patients with recent worsening HF |
| GLP-1 RAs | Not part of GDMT (Semaglutide, Tirazepatide) | ---- | ---- | ---- | Under investigation in clinical trials, but direct role not established for HFrEF treatment | | |

* Consider renal dose adjustments and close monitoring especially in patients with GFR <60 mL/min

Disclaimer: THIS IS NOT MEDICAL, LEGAL OR REIMBURSEMENT ADVICE. This content is provided for informational purposes only as an evidence-based reference guide. No information contained in these materials is intended to be a substitute for professional medical advice, diagnosis, or treatment. Actual determinations of individual patient management, treatment, or documentation decisions remain the independent medical judgment of the respective treating practitioner. Always seek appropriate legal, financial, medical, and consulting advice as needed.

The use of any of these materials is the practitioner's responsibility and information is provided on an "as is" basis. To the extent permitted by law, Ventric Health expressly disclaim all liability and damages of any kind arising out of use, reference to, or reliance on this content. All information is provided in good faith; however, no representation or warranty of any kind, express or implied, is made regarding the accuracy, adequacy, reliability, or completeness of information in these materials. This content is not intended as, and should not be construed to be, medical, legal, financial, reimbursement, or consulting advice.

GDMT Reference Table | HFpEF

| Drug Class | Drug Name | Initial Dose | Target Dose | Titration Comments | Hospitalization Relative Risk Reduction | Mortality Relative Risk Reduction | Other Notable Outcomes |
|---|---|----------------------|-----------------------|--|---|-----------------------------------|---|
| Loop Diuretics (COR 1) | Furosemide, Bumetanide, Torsemide, and Furoscix® (subQ) | varies | varies | Titrate to euvolemia | ---- | ---- | ---- |
| SGLT2 Inhibitors (COR I) | Dapagliflozin (Farxiga®) | 10 mg daily | 10 mg daily | Titration not required | 26% | NS (12%) | <ul style="list-style-type: none"> CV death + HF hospitalization reduction by 18-21% |
| | Empagliflozin (Jardiance®) | 10 mg daily | 10 mg daily | | | | |
| ARBs (COR 2b) | Candesartan | 4-8 mg daily | 32 mg daily | Titrate as tolerated to goal BP | NS | NS | <ul style="list-style-type: none"> No HFpEF benefit, but key for comorbidity & risk factor mgmt.: HTN (first-line) DM + albuminuria: 18% reduction in kidney failure, 56% reduction in progression to macroalbuminuria |
| | Valsartan | 40 mg twice daily | 160 mg twice daily | | | | |
| | Irbesartan | 75-150 mg daily | 300 mg daily | | | | |
| ARNI (COR 2b) | Sacubitril/Valsartan (Entresto®) | 24/26 mg twice daily | 97/103 mg twice daily | Titrate every 2-4 weeks | 15%* | NS | <ul style="list-style-type: none"> Subgroup benefit: Women and LVEF ≤57% (e.g., HFmrEF); 40% reduction in renal composite Caution: Increased hypotension risk |
| MRAs (COR 2b) | Spironolactone* | 12.5-25 mg daily* | 25-50 mg daily | Titration to goal every 4 weeks dependent on potassium levels and renal function | NS | NS | <ul style="list-style-type: none"> CV death + HF hospitalization reduction by 18% |
| | Finerenone (Kerendia®)* | 10-20mg daily* | 40 mg daily | | 18% | NS (7%) | <ul style="list-style-type: none"> CV death + Worsening HF reduction by 16% Decreased urgent HF visits by 37% FDA approved for HFpEF |
| ACE Inhibitors (COR No Recommendation) | Enalapril | 2.5 mg twice daily | 10-20 mg twice daily | Titrate as tolerated to goal BP | NS | NS | <ul style="list-style-type: none"> No HFpEF benefit, but key for comorbidity & risk factor mgmt.: HTN (first-line) DM + albuminuria: 39% reduction in kidney failure CAD/Post-MI: 22% reduction in CV events |
| | Lisinopril | 2.5-5 mg daily | 40 mg daily | | | | |
| | Ramipril | 1.25-2.5 mg daily | 10 mg daily | | | | |
| Beta-Blockers (COR No Recommendation) | Not recommended in isolated HFpEF unless concurrent AF, CAD, or post-MI | ---- | ---- | NA | Uncertain | Uncertain | |
| GLP-1 RAs (Obesity-related HFpEF only with BMI ≥30) (COR No Recommendation) | Semaglutide (Wegovy®) | 0.25 mg weekly | 2.4 mg weekly | Titrate every 4 weeks | 41% | NS | <ul style="list-style-type: none"> KCCQ improvement by 7.8 pts |
| | Tirzepatide (Zepbound®) | 2.5 mg weekly | 15 mg weekly | Titrate every 4 weeks | 38% | NS | <ul style="list-style-type: none"> CV death + worsening HF reduction by 38% |

* Consider renal dose adjustments and close monitoring especially in patients with GFR <60 mL/min

Bring Clarity to Heart Failure Management:

Join clinicians across the country using Vivio to close the diagnostic gap and transform outcomes for their highest-risk patients.

[VentricHealth.com](https://www.ventrichealth.com)

